The Beauty Health Company faces a precarious outlook as it struggles to stabilize its core medical aesthetics business, evidenced by a 6.7% revenue decline in 2026Q1.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | -$0.14+89.5% vs -$1.33 | $69M+1.8% vs $68M |
Q3 2026 Aug 6, 2026 | -$0.40+20.0% vs -$0.50 | $72M-3.2% vs $74M |
Q2 2026 May 7, 2026 | -$0.05+97.2% vs -$1.80 | $65M-2.1% vs $66M |
Q2 2026 Mar 12, 2026 | -$1.20+14.3% vs -$1.40 | $82M+5.4% vs $78M |
Beauty Health NASDAQ: SKIN, referred to as SkinHealth Systems on its earnings call, reported a narrower revenue decline and higher adjusted earnings for the third quarter of 2026, as growth in consumables helped offset weaker equipment sales.
While the top- and bottom-line numbers for SkinHealth Systems Inc. (SKIN) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
LONG BEACH, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- SkinHealth Systems Inc. (NASDAQ: SKIN) (“SkinHealth Systems” or the "Company"), home to flagship brand Hydrafacial®, today announced financial results for the third quarter ended September 30, 2026 (“Q3 2026”).
SkinHealth Systems Inc. (SKIN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Benchmark SKIN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for SkinHealth Systems Inc. (SKIN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $15.71 | $102.23M | -5.60 | -10.02% | -6.33% | -32.11% | — | |
| $116.14 | $6.84B | 80.55 | 24.59% | 4.47% | 7.39% | — | |
| $135.55 | $4.34B | 25.52 | 2.49% | 11.33% | 15.43% | 2.36% | |
| $4.05 | $3.57B | -6.35 | -1.46% | -9.74% | -16.47% | 0.37% | |
| $4.10 | $199.06M | -0.85 | -14.26% | -17.72% | -34.83% | 5.74% | |
| $13.63 | $251.65M | -11.89 | 8.28% | -2.34% | -3.65% | — |
SkinHealth Systems Inc. (SKIN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
SkinHealth Systems Inc. (SKIN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 14, 2026·SEC
Aug 6, 2026·SEC
Jun 22, 2026·SEC
Get notified when SKIN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SkinHealth Systems Inc. (SKIN) stock FAQ — growth, dividends, profitability & financials explained
SkinHealth Systems Inc. (SKIN) reported $288.6M in revenue over the trailing twelve months. Revenue was $300.8M in fiscal year 2025. That is 81% more than the $166.6M of fiscal year 2019.
SkinHealth Systems Inc. (SKIN) revenue fell by 4.4% over the trailing twelve months, compared with the twelve months before.
No. SkinHealth Systems Inc. (SKIN) reported a net loss of $18.3M over the trailing twelve months.
SkinHealth Systems Inc. (SKIN) had a return on equity (ROE) of -32.1% over the trailing twelve months. A negative ROE means the company lost money over the period.
SkinHealth Systems Inc. (SKIN) generated $22.2M in free cash flow over the trailing twelve months.
